Once-weekly ALTUVIIIO is a first-in-class, high-sustained Factor VIII replacement therapy that provides normal to near-normal levels (>40%) for most of the week in adults.†
Watch how switching to ALTUVIIIO can make a difference
Achieve higher Factor VIII levels with ALTUVIIIO1

Proven bleed protection with once-weekly dosing3
- Routine prophylaxis (n=128) resulted in a median ABR of 0.0 (Q1, Q3: 0.0-1.0) and a mean ABR of 0.7 (95% CI: 0.5-1.0)§
- Significant improvement in bleed protection in the intrapatient comparison group (n=78): 77% reduction in mean ABR vs prestudy Factor VIII prophylaxis§
* Based on specialty pharmacy channel and HTC-reported data from October 2023 to January 2025.
† Data from the Phase 3 XTEND-1 study in 125 adults ≥18 years receiving a weekly IV infusion of 50 IU/kg ALTUVIIIO.1
‡ Mean trough level was computed using available measurements at Week 52/end of study PK sampling visit for the adult population in the XTEND-1 study (n=123).1
§ Based on treated bleeds.1
Indication
ABR=annualized bleed rate; aPTT=activated partial thromboplastin time; CI=confidence interval; IU=international unit; IV=intravenous; PK=pharmacokinetics; Q1=25th percentile; Q3=75th percentile; SD=standard deviation.
References: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 2. Data on file. January 2025. 3.von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318.